Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,991 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Martino EA, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pompa A, Vincelli D, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Ferretti E, Bertuglia G, Nappi D, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P. Gentile M, et al. Among authors: galli m. Haematologica. 2024 Jan 1;109(1):245-255. doi: 10.3324/haematol.2023.283251. Haematologica. 2024. PMID: 37439329 Free PMC article.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
Zamagni E, Oliva S, Gay F, Capra A, Rota-Scalabrini D, D'Agostino M, Belotti A, Galli M, Racca M, Zambello R, Gamberi B, Albano D, Bertamini L, Versari A, Grasso M, Sgherza N, Priola C, Fioritoni F, Patriarca F, De Cicco G, Villanova T, Pascarella A, Zucchetta P, Tacchetti P, Fanti S, Mancuso K, Barbato S, Boccadoro M, Musto P, Cavo M, Nanni C. Zamagni E, et al. Among authors: galli m. EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37396807 Free PMC article.
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Furlan A, Cea M, Pavan L, Galli M, Clissa C, Mangiacavalli S, Cafro AM, Girlanda S, Patriarca F, Minotto C, Bertoldero G, Barilà G, Pascarella A, Lico A, Paolini R, Rabassi N, Pescosta N, Porrazzo M, De Sabbata G, Pompa A, Bega G, Cavallin S, Guidotti F, Marcatti M, Rupolo M, Belotti A, Gherlinzoni F, Zambello R. Furlan A, et al. Among authors: galli m. Cancer Med. 2024 Apr;13(7):e7071. doi: 10.1002/cam4.7071. Cancer Med. 2024. PMID: 38558233 Free PMC article.
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment.
Oriol A, Dimopoulos M, Schjesvold F, Beksac M, Facon T, Dhanasiri S, Guo S, Mu Y, Hong K, Gentili C, Galli M, Yagci M, Larocca A, Richardson P, Weisel K. Oriol A, et al. Among authors: galli m. Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):165-176.e4. doi: 10.1016/j.clml.2023.10.009. Epub 2023 Nov 8. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38072743 Free article.
Search for exotic decays of the Higgs boson to a pair of pseudoscalars in the μμbb and ττbb final states.
CMS Collaboration; Hayrapetyan A, Tumasyan A, Adam W, Andrejkovic JW, Bergauer T, Chatterjee S, Damanakis K, Dragicevic M, Del Valle AE, Hussain PS, Jeitler M, Krammer N, Liko D, Mikulec I, Schieck J, Schöfbeck R, Schwarz D, Sonawane M, Templ S, Waltenberger W, Wulz CE, Darwish MR, Janssen T, Van Mechelen P, Bols ES, D'Hondt J, Dansana S, De Moor A, Delcourt M, El Faham H, Lowette S, Makarenko I, Müller D, Sahasransu AR, Tavernier S, Tytgat M, Van Putte S, Vannerom D, Clerbaux B, De Lentdecker G, Favart L, Hohov D, Jaramillo J, Khalilzadeh A, Lee K, Mahdavikhorrami M, Malara A, Paredes S, Pétré L, Postiau N, Thomas L, Bemden MV, Velde CV, Vanlaer P, De Coen M, Dobur D, Hong Y, Knolle J, Lambrecht L, Mestdach G, Rendón C, Samalan A, Skovpen K, Van Den Bossche N, Wezenbeek L, Benecke A, Bruno G, Caputo C, Delaere C, Donertas IS, Giammanco A, Jaffel K, Jain S, Lemaitre V, Lidrych J, Mastrapasqua P, Mondal K, Tran TT, Wertz S, Alves GA, Coelho E, Hensel C, Menezes De Oliveira T, Moraes A, Rebello Teles P, Soeiro M, Aldá Júnior WL, Alves Gallo Pereira M, Barroso Ferreira Filho M, Brandao Malbouisson H, Carvalho W, Chinellato J, Da Costa EM, Da Silveira GG, De Jesus Damiao D, Fonseca De… See abstract for full author list ➔ CMS Collaboration, et al. Among authors: galli m. Eur Phys J C Part Fields. 2024;84(5):493. doi: 10.1140/epjc/s10052-024-12727-4. Epub 2024 May 14. Eur Phys J C Part Fields. 2024. PMID: 38757620 Free PMC article.
Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis.
Galli M, Occhipinti G, Benenati S, Laborante R, Ortega-Paz L, Franchi F, D'Amario D, Nerla R, Castriota F, Frati G, Biondi-Zoccai G, Sciarretta S, Angiolillo DJ. Galli M, et al. Eur Heart J Cardiovasc Pharmacother. 2024 May 16:pvae036. doi: 10.1093/ehjcvp/pvae036. Online ahead of print. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38754988
1,991 results